Filgotinib-d4 (Synonyms: GLPG0634-d4) |
Katalog-Nr.GC46148 |
Filgotinib-d4 (GLPG0634-d4) ist das mit Deuterium gekennzeichnete Filgotinib. Filgotinib (GLPG0634) ist ein selektiver JAK1-Inhibitor mit IC50-Werten von 10 nM, 28 nM, 810 nM und 116 nM fÜr JAK1, JAK2, JAK3 bzw. TYK2.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2041095-50-3
Sample solution is provided at 25 µL, 10mM.
Filgotinib-d4 is intended for use as an internal standard for the quantification of filgotinib by GC- or LC-MS. Filgotinib is a JAK1 inhibitor (IC50 = 10 nM).1 It is selective for JAK1 over JAK3 (IC50 = 810 nM) but also inhibits JAK2 and tyrosine kinase 2 (Tyk2; IC50s = 28 and 116 nM, respectively), as well as Abl, FLT1, -3 and -4, FMS, Mer, and TBK1 activity by greater than 35% in a panel of 177 tyrosine kinases at 1 μM. Filgotinib inhibits IL-6-induced phosphorylation of STAT1 in CD4+ T cells with an IC50 value of 629 nM in isolated human whole blood. It reduces hind paw macrophage and T cell infiltration and bone erosion in a rat model of collagen-induced arthritis when administered at doses ranging from 0.1 to 30 mg/kg per day for 15 days.
|1. Van Rompaey, L., Galien, R., van der Aar, E.M., et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J. Immunol. 191(7), 3568-3577 (2013).
Average Rating: 5
(Based on Reviews and 29 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *